Search

Your search keyword '"Kang, Xindan"' showing total 19 results
Start Over Author "Kang, Xindan"
19 results on '"Kang, Xindan"'

11. Pharmacogenomic landscape of head and neck squamous cell carcinoma informs precision oncology therapy

Author

Gu, Ziyue, primary, Yao, Yanli, additional, Yang, Guizhu, additional, Zhu, Guopei, additional, Tian, Zhen, additional, Wang, Rui, additional, Wu, Qi, additional, Wang, Yujue, additional, Wu, Yaping, additional, Chen, Lan, additional, Wang, Chong, additional, Gao, Jiamin, additional, Kang, Xindan, additional, Zhang, Jie, additional, Wang, Lizhen, additional, Duan, Shengzhong, additional, Zhao, Zhongming, additional, Zhang, Zhiyuan, additional, and Sun, Shuyang, additional

Published
2022
Full Text
View/download PDF

13. Retinoic Acid-Induced 2 (RAI2) Is a Novel Antagonist of Wnt/β-Catenin Signaling Pathway and Potential Biomarker of Chemosensitivity in Colorectal Cancer

Author

Zhang, Weitao, primary, Kong, Lu, additional, Zhu, Hongbin, additional, Sun, Decong, additional, Han, Quanli, additional, Yan, Bin, additional, Cui, Zhi, additional, Zhang, Weiwei, additional, Zhang, Shurong, additional, Kang, Xindan, additional, Dai, Guanghai, additional, Qian, Niansong, additional, and Yan, Wenji, additional

Published
2022
Full Text
View/download PDF

14. Clinical Analysis and Prognostic Significance of Hepatitis B Virus Infections with Diffuse Large B-Cell Lymphoma

Author

Kang,Xindan, Bai,Li, Han,Chun, and Qi,Xiaoguang

Subjects
Cancer Management and Research, hemic and lymphatic diseases
Abstract

Xindan Kang,1,2 Li Bai,1 Chun Han,1 Xiaoguang Qi1 1Department of Oncology, The First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing 100853, People’s Republic of China; 2Department of Graduate Administration, Chinese PLA General Hospital/Medical School of Chinese PLA, Beijing, People’s Republic of ChinaCorrespondence: Li Bai Email baili_0795@163.comBackground: China is a high endemic area for the hepatitis B virus (HBV). The studies established the epidemiology between HBV and diffuse large B-cell lymphoma (DLBCL), but further research is necessary to clarify the potential link between HBV and DLBCL.Patients and Methods: A totalof 319 patients diagnosed with DLBCL were recruited as cases at First Medical Centre of Chinese PLA General Hospital from September 2010 to December 2018. During the same time, two age- and sex-matched controls were selected for each case, and the control groups comprised of 319 patients with non-hematological malignancy and 319 subjects with non-malignant conditions. Relative risk of developing DLBCL among individuals tested positive for hepatitis B surface antigen was calculated. After that, we retrospectively analyzed clinical data from DLBCL patients with different HBV infection statuses.Results: The HBV infection rate of patients with DLBCL (11.60%) was significantly higher than the other two control groups (5.02% and 4.08%), indicating the risk of DLBCL may increased in HBV infections. Meanwhile, this study demonstrated an independent association between HBV infection and poorer clinical outcomes.Conclusion: Our study demonstrated that HBV infection may play an important role in the pathogenesis of DLBCL and show poor outcomes in HBV-endemic China.Keywords: case–control study, diffuse large B-cell lymphoma, hepatitis B viral

Published
2020

15. Penpulimab (Anti-PD-1) combined with anlotinib as first-line therapy for unresectable hepatocellular carcinoma (uHCC): Updated results from a phase Ib/II study.

Author

Jiao, Shun Chang, primary, BAI, LI, additional, Dong, Jiahong, additional, Bai, Chunmei, additional, Hu, Chunhong, additional, Shen, Liangfang, additional, Qin, Qun, additional, Bai, Yuxian, additional, Fan, Jia, additional, Zang, Aimin, additional, Zhu, Yanyun, additional, Han, Chun, additional, Li, Juan, additional, Zhang, Pengfei, additional, Ye, Sisi, additional, Kang, Xindan, additional, Qiao, Qian, additional, Wang, Zhongmin Maxwell, additional, Li, Baiyong, additional, and Xia, Yu, additional

Published
2021
Full Text
View/download PDF

18. Clinical activity and safety of penpulimab (Anti-PD-1) with anlotinib as first-line therapy for advanced hepatocellular carcinoma (HCC).

Author

Jiao, Shun Chang, primary, Bai, Li, additional, Dong, Jiahong, additional, Bai, Chunmei, additional, Hu, Chunhong, additional, Shen, Liangfang, additional, Qin, Qun, additional, Bai, Yuxian, additional, Fan, Jia, additional, Zang, Aimin, additional, Han, Chun, additional, Zhu, Yanyun, additional, Li, Juan, additional, Zhang, Pengfei, additional, Ye, Sisi, additional, Kang, Xindan, additional, Qiao, Qian, additional, Song, Weifeng, additional, Li, Baiyong, additional, and Xia, Yu, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results